➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Express Scripts
Dow

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Patent: 8,080,248

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,080,248
Title:Method of treating rheumatoid arthritis with an IL-6R antibody
Abstract: The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory drug (NSAID), a glucocorticoid, a disease-modifying anti-rheumatic drug (DMARD), or a TNF-alpha antagonist, T-cell blocker, anti-CD20 antibody, an IL-1, JAK or IL-17 antagonist, or any combination thereof.
Inventor(s): Radin; Allen (New York, NY), Stevens; Sean (San Diego, CA), Huang; Tammy T. (Goldens Bridge, NY), Martin; Joel H. (Putnam Valley, NY), Fairhurst; Jeanette L. (White Plains, NY), Rafique; Ashique (Yonkers, NY), Smith; Eric (New York, NY), Pobursky; Kevin J. (Beacon, NY), Papadopoulos; Nicholas J. (LaGrangeville, NY), Fandl; James P. (LaGrangeville, NY), Chen; Gang (Yorktown Heights, NY), Karow; Margaret (Camarillo, CA)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:12/780,006
Patent Claims:see list of patent claims

Details for Patent 8,080,248

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2026-06-02 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2026-06-02 RX Orphan search
Janssen Biotech SIMPONI ARIA golimumab INJECTABLE; INJECTION 125433 001 2013-07-18   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2026-06-02 RX search
Centocor Ortho Biotech Inc SIMPONI golimumab INJECTABLE; INJECTION 125289 001 2009-04-24   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2026-06-02 RX Orphan search
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2026-06-02 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Dow
Johnson and Johnson
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.